MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) has entered an exclusive three-year agreement with Elite DNA Behavioral Health to become the sole provider of transcranial magnetic stimulation (TMS) devices across the Florida-based mental health network’s 30-plus clinics. The deal marks a significant step in Neuronetics’ strategy to broaden access to its NeuroStar TMS therapy for patients with depression.
The collaboration also integrates Neuronetics’ Greenbrook platform to deliver operational and patient-support services to Elite DNA, including scheduling, TMS consultations, and PHQ-10 processing. The arrangement is designed to streamline administrative operations and allow clinicians to focus more directly on patient care.
“We are excited to further build upon our commercial partnership with Elite DNA Behavioral Health. Together, we’re expanding NeuroStar’s reach and helping even more patients access proven, life-changing TMS therapy through a scalable, systemized model of care,” said Keith J. Sullivan, President and CEO of Neuronetics. “This collaboration operationalizes one of the stated strategic values of the Greenbrook acquisition and offers a model for delivering this service to other organizations in the future.”
Elite DNA Behavioral Health, one of Florida’s largest and fastest-growing mental health networks, said the partnership aligns with its mission to expand access to evidence-based treatment options for patients across the state.
“This partnership reflects our shared commitment to breaking barriers in mental health treatment and ensuring patients can access the care they need,” said Elizabeth Dosoretz, LCSW, Founder and CEO of Elite DNA Behavioral Health. “Working with Neuronetics allows us to continue advancing our mission to make comprehensive, evidence-based care available in every community we serve.”
Chief Medical Officer Dr. Omar Rieche said the collaboration enhances patient outcomes through closer coordination between clinical and support teams. “Partnering with Neuronetics as an extension of our care teams allows us to deliver a more seamless patient experience, expand access to advanced treatment options, and uphold the highest clinical standards across all of our clinics,” he said.
The partnership began with a pilot program in late 2025, with full implementation planned for 2026 as Neuronetics scales its integrated care model across Elite DNA’s statewide network.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.